Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biological Characterization of Advanced ALK-rearranged Non-small Cell Lung (NSCLC) Cancer Included in EXPLOREALK Study

NCT05122806 is registered in ClinicalTrials.gov with Groupe Francais De Pneumo-Cancerologie as lead sponsor.

NCT NCT05122806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biological Characterization of Advanced ALK-rearranged Non-small Cell Lung (NSCLC) Cancer Included in EXPLOREALK Study
Lead sponsor
Groupe Francais De Pneumo-Cancerologie
Phase
Not applicable
Overall status
Recruiting
Start date
September 22, 2021
Completion date
June 30, 2027
Enrollment
100 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement positive, non-small cell lung cancer